Summary
This article presents the 48-week results of the Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis and Multiple Joint Involvement Who Have Poor Response to Methotrexate [GO KIDS; NCT01230827].
- Rheumatology Clinical Trials Arthritis
 - Rheumatological Autoimmune Disorders
 
- Rheumatology Clinical Trials
 - Rheumatology
 - Arthritis
 - Rheumatological Autoimmune Disorders
 
- © 2014 MD Conference Express®
 










